Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis

Inclusion Criteria

• •Age ≥ 18 years.
• •Diagnosed within the past 3 months with stage I-II (based on chest CT) treatment-naive pulmonary sarcoidosis, meeting the following: A. Histopathological diagnosis of sarcoidosis via tissue biopsy (bronchial mucosa, intrathoracic lymph nodes, lung, pleura, etc.) obtained during bronchoscopy; B. Chest HRCT showing mediastinal and hilar lymphadenopathy, with or without pulmonary infiltrates (nodules, patchy opacities, ground-glass opacities, etc.); C. CT stage confirmed independently by at least two experts in the field (among three experts reviewing the chest HRCT images).
• •Requiring systemic glucocorticoid therapy.
• •Able to complete scheduled follow-up visits.
• •Patient and family members understand the study protocol, are willing to participate in this study, and are able to provide written informed consent.